24-06-2010: MorphoSys AG announced that it will receive a clinical milestone payment from Centocor Ortho Biotech Inc. (formerly known as: Centocor, Inc.) in connection with the initiation of a phase 1 clinical trial of a HuCAL-derived antibody in the therapeutic area of inflammatory and autoimmune diseases. The target against which the antibody is directed is undisclosed.
As part of the Centocor Ortho Biotech Inc. collaboration in 2007, a HuCAL antibody became the first from MorphoSys to be developed in two different therapeutic areas - oncology and immunology and in 2009, a different HuCAL antibody advanced in the therapeutic area of inflammation into a phase 1 trial. Today's announcement marks the start of a fourth clinical trial that will be running HuCAL antibodies. Further pre-clinical programs are ongoing.
"Our clinical pipeline is progressing very well, and we expect significant progress in this regard during the course of 2010 with up to six new partnered programs advancing into the clinic," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "We are delighted to see another antibody program advance into phase 1 clinical trials."
MorphoSys AG announced that the Company will nominate Ms. Karin Eastham and Dr. Marc Cluzel as new members of the Supervisory Board at the Company's Annual Shareholder Meeting on Thursday, May 31, 2012. Ms. Eastham and Dr. Cluzel will replace Prof. Dr. Jürgen Drews and Dr. Metin Colpan. Pro ... more
MorphoSys AG announced that the US Patent and Trademark Office (USPTO) has granted a patent covering the Company's cancer compound MOR202. The new patent (US 8,088,896) covers MorphoSys's HuCAL antibody against CD38 as well as pharmaceutical compositions comprising the same, and has a sched ... more
MorphoSys AG announced that a phase 1b clinical trial evaluating MOR103, a human monoclonal antibody to GM-CSF (granulocyte macrophage-colony stimulating factor), in patients with multiple sclerosis (MS) is now open for enrollment, thereby adding a second indication to the development progr ... more
As one of the leading public biotech companies in Europe, we are committed to developing the medicines of the future. Building on our portfolio of innovative antibody technologies, we are actively pursuing new therapeutic approaches in close collaboration with the world‘s foremost pharmaceu ... more
MorphoSys AG, located in Martinsried/Munich, is one of the worlds leading biotechnology companies focusing on fully human antibodies. With its unique technologies, MorphoSys is developing the next generation of therapeutic antibodies which can be used not only for research and diagnostics b ... more
MorphoSys AG announced that it has received a clinical milestone payment from Centocor Ortho Biotech Inc. in connection with the regulatory filing of a clinical trial application for a phase 1 clinical trial of a HuCAL-derived antibody in the therapeutic area of inflammatory and autoimmune ... more
MorphoSys AG announced that it will receive a clinical milestone payment from Centocor Ortho Biotech Inc. (formerly known as: Centocor, Inc.) in connection with the initiation of a phase 1 clinical trial of a HuCAL-derived antibody in the therapeutic area of inflammatory and autoimmune dis ... more
Centocor Ortho Biotech Inc. announced that it has acquired RespiVert Ltd., a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases. The company's lead compounds, RV-568 and RV-1088, narrow spectrum kinase inhib ... more